ZabBio is developing a human contraceptive antibody for use as an on demand method of female contraception. The antibody potently agglutinates sperm as well as traps sperm in cervical mucus. Both of these mechanisms of action prevent sperm from ascending the female reproductive tract and fertilizing eggs.
The antibody-based product, ZB-06, is formulated as a vaginal film. A Phase 1 clinical trial was completed in 2022 at the Jones Institute for Reproductive Medicine of the Eastern Virginia Medical School (EVMS). A dose finding phase 2a is planned for 2024. This project is a collaboration of Boston University, ZabBio, KBio Inc. and EVMS, and is funded by an NICHD Contraceptive Research Center grant (2P50HD096957-02).